World Orphan Drug Alliance
World Orphan Drug Alliance is a private pharmaceutical company founded in 2022 that distributes and commercializes orphan drugs and rare disease therapies on behalf of pharmaceutical partners, operating as a multi-partner commercialization alliance.
- Company typePrivate
- Founded2022
- Headquarters—
- Headcount101–250
- GTM typeB2B
- OfferingServices
What World Orphan Drug Alliance does
World Orphan Drug Alliance (WODA) is a privately held, for-profit commercial entity founded in 2022 that distributes and commercializes orphan drugs and rare disease therapies on behalf of pharmaceutical partners. The company operates as a dedicated channel for rare disease manufacturers, addressing a market where patient populations are small, distribution and reimbursement pathways are fragmented, and specialized commercialization expertise is required. WODA's "Alliance" positioning indicates a multi-partner consortium model rather than a single-asset distributor, suggesting intent to aggregate demand across multiple sponsors and therapy areas.
WODA reports a headcount of 101–250 employees, indicating an organization that has scaled rapidly since founding. The company's website (woda-alliance.com) rendered only a loading/verification screen at the time of data capture, and no additional product, technology, partnership, or geographic information was available beyond the firm's stated distribution and commercialization role. No specific therapy areas, named partners, revenue figures, funding rounds, or geographic footprint are disclosed in the available source data, which constrains visibility into the operational details of the business.
The underlying business model is implicit B2B commercialization services for orphan drug manufacturers, likely generating revenue through distribution margins, commercialization service fees, or a hybrid model tied to partner product performance. In the orphan drug category, where therapies often command high unit prices and require specialized patient access programs, such a model can scale revenue with relatively limited headcount. However, with no disclosed financials, partner roster, or product pipeline, the company's revenue mechanics, contract structures, and competitive positioning cannot be precisely characterized from the available data.
World Orphan Drug Alliance firmographics
Firmographics- Name
- World Orphan Drug Alliance
- Website
- https://woda-alliance.com
- Company type
- Private
- Founded year
- 2022
- Headcount range
- 101–250 employees
- Short description
- World Orphan Drug Alliance is a private pharmaceutical company founded in 2022 that distributes and commercializes orphan drugs and rare disease therapies on behalf of pharmaceutical partners, operating as a multi-partner commercialization alliance.
- Ownership category
- akta.pro rank
World Orphan Drug Alliance industry classification
Industry- Product category
- Orphan Drug Distribution and Commercialization
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
World Orphan Drug Alliance business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
World Orphan Drug Alliance product offering
Product offeringCore offering
World Orphan Drug Alliance distributes and commercializes orphan drugs and rare disease therapies on behalf of pharmaceutical partners. The company supports pharmaceutical manufacturers in bringing rare disease treatments to patients by handling distribution logistics and market commercialization in the orphan drug segment.
Differentiator
Problem solved
Functional benefit
Products and services
- Orphan drug distribution and commercialization services End-to-end distribution and commercialization of orphan drugs and rare disease therapies, delivered on behalf of pharmaceutical partners who lack dedicated rare disease infrastructure.
Companies that use World Orphan Drug Alliance
Customer profileIdeal customer profiles1 record
World Orphan Drug Alliance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
World Orphan Drug Alliance partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights3 records
World Orphan Drug Alliance competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Clinical-to-commercial biopharma services company offering commercialization solutions that overlap with WODA's mandate to bring partner drugs to market, though with a broader service portfolio.
- Inizio: Global pharma commercialization and advisory group formed from the merger of Ashfield, Huntsworth, and others. Provides commercialization, market access, and distribution-adjacent services that overlap with WODA's partner-facing model.
- McKesson: Global pharmaceutical distributor with specialty and rare disease distribution capabilities (e.g., McKesson Plasma and Biologics). Represents the established incumbent WODA must compete against for partner mandates.
- Cencora (formerly AmerisourceBergen): One of the world's largest pharmaceutical distributors with a dedicated specialty/rare disease business serving biotech partners. Much larger and broader than WODA, but directly competes for orphan drug distribution mandates.
- Eversana: Large US-based pharma commercialization services provider with dedicated rare disease and specialty therapy offerings. Broader portfolio than WODA but overlaps directly in orphan drug commercialization services for biopharma partners.
Direct peers
- Clinigen Group: UK-headquartered pharma services company providing access to unlicensed, rare, and specialty medicines globally through named-patient and managed access programs. Directly comparable in providing cross-border rare disease drug access on behalf of pharma partners.
- Medison Pharma: Israel-based specialty pharma company that commercializes and distributes rare disease and oncology therapies for biotech partners across multiple geographies. Highly comparable to WODA's orphan drug distribution and commercialization model.
- BAP Pharma: UK-based pharmaceutical company specializing in unlicensed and orphan medicine supply to healthcare professionals and patients worldwide. Comparable niche focus on rare/orphan drug access and distribution.
Emerging players
- Sobi (Swedish Orphan Biovitrum): Rare disease-focused pharmaceutical company that both develops and distributes orphan drugs internationally. Comparable in rare disease focus, though Sobi is a product-owning developer rather than a pure distribution partner.
Regional players
- Accord Healthcare (Intas Pharmaceuticals): Specialty and rare disease pharmaceutical company with growing international distribution across Europe, North America, and Asia-Pacific. Comparable specialty pharma distribution focus, though primarily product-owning rather than partner-driven distribution.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
World Orphan Drug Alliance social profiles
Digital presenceWorld Orphan Drug Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
World Orphan Drug Alliance leadership team
Management profileNumber of profiles
World Orphan Drug Alliance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
World Orphan Drug Alliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about World Orphan Drug Alliance
What does World Orphan Drug Alliance do?
World Orphan Drug Alliance distributes and commercializes orphan drugs and rare disease therapies on behalf of pharmaceutical partners. The company supports pharmaceutical manufacturers in bringing rare disease treatments to patients by handling distribution logistics and market commercialization in the orphan drug segment.
When was World Orphan Drug Alliance founded?
World Orphan Drug Alliance was founded in 2022. It employs 101 to 250 people.
Who are World Orphan Drug Alliance's main competitors?
Broad incumbents on record are Syneos Health, Inizio, McKesson, Cencora (formerly AmerisourceBergen) and Eversana. Direct peers are Clinigen Group, Medison Pharma and BAP Pharma. Sobi (Swedish Orphan Biovitrum) is listed as an emerging player. Accord Healthcare (Intas Pharmaceuticals) is listed as a regional player.
Does World Orphan Drug Alliance have an API?
No public API is recorded for World Orphan Drug Alliance.
What industry is World Orphan Drug Alliance in?
World Orphan Drug Alliance's product category is Orphan Drug Distribution and Commercialization. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 424210 and its SIC code is 5122.